OncoMatch/Clinical Trials/NCT07174570
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
Is NCT07174570 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Durvalumab and Tremelimumab for advanced hepatocellular carcinoma.
Treatment: Celecoxib · Durvalumab · Tremelimumab — This phase II trial tests how well the combination of celecoxib with durvalaumab and tremellimumab works in treating patients with hepatocellular cancer (liver cancer) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Celecoxib belongs to the family of drugs called nonsteroidal anti-inflammatory agents and is used to reduces pain. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving celecoxib with durvalaumab and tremellimumab may better treat patients with advanced or metastatic liver cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Exception: allowed if >6 months since last ICI
Patients who have had immune checkpoint inhibitors (ICI) therapy within 6 months prior to entering the study
Lab requirements
Blood counts
Platelet count > 100,000 cells/ul; Hemoglobin (Hb) > 9g/dl; Absolute neutrophil count > 1000 cells/dl
Kidney function
Glomerular filtration rate (GFR) > 60ml/min (based on creatine, and cystatin C estimation where applicable)
Liver function
Total bilirubin < 3mg/dl; Albumin > 3g/dl
Cardiac function
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class IIB or better.
Platelet count > 100,000 cells/ ul; Hemoglobin (Hb) > 9g/dl; Absolute neutrophil count > 1000 cells/dl; Albumin > 3g/dl; Total bilirubin < 3mg/dl; Glomerular filtration rate (GFR) > 60ml/min; Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class IIB or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Grady Health System · Atlanta, Georgia
- Emory University Hospital Midtown · Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
- Emory Saint Joseph's Hospital · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify